Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | MDM4 | O15151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31377147 | 0.92 | BACE1 (0.46) | BACE1DPP8DPP9KMT2AEPHX2 | |
| SCHEMBL9281160 | 0.92 | BACE1 (0.46) | BACE1DPP8DPP9KMT2AEPHX2 | |
| SCHEMBL22291368 | 0.89 | BACE1 (0.42) | BACE1DPP8DPP9KMT2AEPHX2 | |
| SCHEMBL30326970 | 0.87 | BACE1 (0.41) | BACE1DPP8DPP9KMT2AEPHX2 | |
| SCHEMBL14508508 | 0.86 | BACE1 (0.45) | BACE1DPP8DPP9KMT2AEPHX2 | |
| SCHEMBL12869622 | 0.86 | BACE1 (0.45) | BACE1DPP8DPP9KMT2AEPHX2 | |
| SCHEMBL555165 | 0.85 | BACE1 (0.44) | BACE1DPP8DPP9KMT2AEPHX2 | |
| SCHEMBL1404239 | 0.84 | BACE1 (0.48) | BACE1DPP8DPP9KMT2AEPHX2 | |
| SCHEMBL30202258 | 0.84 | BACE1 (0.48) | BACE1DPP8DPP9KMT2AEPHX2 | |
| SCHEMBL554899 | 0.84 | BACE1 (0.42) | BACE1DPP8DPP9KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331722-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BACE1 2417/4885DPP8 3942/4885DPP9 4147/4885 |
| US-20230142883-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BACE1 2417/4885DPP8 3942/4885DPP9 4147/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BACE1 2417/4885DPP8 3942/4885DPP9 4147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.